However, throughout time, precision medicine has discovered several soluble biomarkers that are predictive of diagnosis, prognosis, and therapy response in RA, including myeloid-related protein 8/14, cellular, and autoantibodies (ACPA, anti-carbamylated protein antibodies 14-3-3, and anti-protein-arginine deiminases antibodies 3/4) [135]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.